Sotagliflozin Diminishes Risk of Heart Failure Events
Lexicon Pharmaceuticals, Inc. announced findings from a new post hoc analysis of clinical data, which demonstrated that sotagliflozin, a dual oral inhibitor of sodium-glucose transport (SGLT) 1 and SGLT2, decreased the risk of heart failure (HF)–related …